Source:		MedGen UID: 406297


			An orally available peptidomimetic small
			molecule with activity against hepatitis C virus
			(HCV). Telaprivir is a selective protease inhibitor
			that targets the viral HCV NS3-4A serine
			protease and disrupts processing of viral
			proteins and formation of a viral replication

			Related Concepts
			Boceprevir response
			Peginterferon alfa-2a response
			Peginterferon alfa-2b response
			Ribavirin response
			Telaprevir response
			protease inhibitors

			32275694 Pre-existing resistance associated
			polymorphisms to NS3 protease inhibitors in
			treatment naïve HCV positive Pakistani patients.

			32245397 Ombitasvir/paritaprevir/ritonavir &
			dasabuvir ± ribavirin following protease inhibitors
			failure - a prospective multi-centre trial.

			31251007 A rare and severe cutaneous
			adverse effect of telaprevir: drug rash with
			eosinophilia and systemic symptoms.

			31227109 Efficacy of telaprevir-based therapy
			in stable liver transplant patients with chronic
			genotype 1 hepatitis C.

			31221866 Cost-effectiveness analysis of
			sofosbuvir plus ribavirin in patients with
			genotype 2 chronic hepatitis C: an analysis with
			real world outcomes from a multicentre cohort
			in Japan.

			31186844 Managing drug-drug interactions
			with boceprevir and telaprevir.

			31157007 Anaemia predictors in patients with
			chronic hepatitis C treated with ribavirin and
			direct-acting antiviral agents.

			31153437 Curing Chronic Hepatitis C: A Cost
			Comparison of the Combination Simeprevir
			Plus Sofosbuvir vs. Protease-Inhibitor-Based
			Triple Therapy.

			31153427 Aplastic Anemia and Severe
			Myelosuppression with Boceprevir or
			Simeprevir-Containing Hepatitis C Virus

			31143073 Ombitasvir/paritaprevir/ritonavir +
			dasabuvir +/- ribavirin in real world hepatitis C

			31108456 Effectiveness and
			Cost-Effectiveness of Triple Therapy with
			Telaprevir and Boceprevir for Chronic Hepatitis
			C: A Decision Analysis from the Brazilian Public
			Health System Perspective.

			30880098 Prevalence of baseline NS3
			resistance-associated substitutions (RASs) on
			treatment with protease inhibitors in patients
			infected with HCV genotype 1.

			30862625 Mechanistic Evaluation of the
			Complex Drug-Drug Interactions of Maraviroc:
			Contribution of Cytochrome P450 3A,
			P-Glycoprotein and Organic Anion Transporting
			Polypeptide 1B1.

			30674624 Validating Enterovirus D68-2Apro as
			an Antiviral Drug Target and the Discovery of
			Telaprevir as a Potent D68-2Apro Inhibitor.

			30649540 Characterisation of healthy
			donor-derived T-cell responses specific to
			telaprevir diastereomers.

			30566559 DRESS syndrome induced by
			telaprevir: a potentially fatal adverse event in
			chronic hepatitis C therapy.

			30445916 The efficacy of
			paritaprevir/ritonavir/ombitasvir+dasabuvir and
			ledipasvir/sofosbuvir is comparable in patients
			who failed interferon-based treatment with first
			generation protease inhibitors - a multicenter
			cohort study.

			30422370 High response and re-infection rates
			among people who inject drugs treated for
			hepatitis C in a community needle and syringe

			30402614 Rare drug allergies: Review on
			prevalence and test procedures.

			30288304 A new paradigm evaluating cost per
			cure of HCV infection in the UK.

			30274834 HCV core antigen as an alternative
			to HCV RNA testing in the era of direct-acting
			antivirals: retrospective screening and
			diagnostic cohort studies.

			30227075 Telaprevir-Induced Renal Adverse
			Events in Japanese Patients Reported in the
			PMDA Adverse Drug Reactions Reporting

			Clinical Trials
			3710252 A Study to Investigate HCV Response
			Rates in Real World Patients: HEARTLAND

			3420300 EBR/GZR for HCV-1b Patients
			Receiving Hemodialysis

			3324633 Inter Cohorts and Clinical Centres
			Collaborations of Subjects Co-infected With
			HIV and HCV

			3268317 Neuropsychiatric Adverse Effects in
			Patients With Chronic Hepatitis C Treated by
			Direct Acting Antiviral Drugs

			3241823 Assessment of Patients With
			Hepatitis C Virus Related Liver Cirrhosis After
			Sustained Response to Direct Acting Anti Viral

			2881034 Ribavirin Bioavailability After Telaprevir

			2874066 PrOD for Non-Cirrhotic Patients With
			HCV-1b Receiving Hemodialysis

			2825212 Efficacy of All-Oral Anti-Viral Therapy
			for Symptomatic Hepatitis C Virus
			Infection-Related Cryoglobulinemia

			2799355 Treatment of Chronic Hepatitis With
			Sofosbuvir in Combination With Ribavirin With
			or Without Pegylated Interferon: North India
			Gastroenterology Consortium

			2758509 Impact of Antiviral Therapy on
			Gastroesophageal Varices.

			2734173 Pilot HCV Direct Acting Antiviral
			Therapy and Metabolism

			2646111 Ombitasvir/Paritaprevir/Ritonavir and
			Dasabuvir With and Without Ribavirin in
			Protease-Inhibitors ("PI") Failures

			2545335 Neutrophil Function During Therapy
			With Protease Inhibitors in Chronic Hepatitis C

			2505243 Evaluation of RIBAvirin Plasma
			COncentrations in Patients With Chronic
			Hepatitis C Infection Routinely Treated With
			Modern DAA Regimens

			2452814 Long Term Extension Study is
			Designed to Monitor Long-Term Efficacy and
			Safety of Miravirsen Sodium in Combination
			With Telaprevir and Ribavirin in Subjects With
			Chronic Hepatitis C Virus Genotype 1 Infection

			2333292 Efficacy and Safety of Therapy
			Against HCV Based on Direct-acting Antivirals
			in Real-life Conditions

			2247440 HCV-HIV Co-infected Patient Cohort
			in Thailand

			2124044 Safety, Tolerability, and Efficacy of
			Asunaprevir and Daclatasvir in Subjects
			Coinfected With HIV-HCV

			2113631 Comparative Effectiveness and
			Tolerability of Boceprevir vs Telaprevir

			2112630 Boceprevir in End Stage Renal
			Disease (ESRD)

     		                         Embed       Tweet       Print